This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Osteogenesis imperfecta type III - progressive deforming

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Type III is a severely progressive deforming variety of osteogenesis imperfecta with an autosomal dominant pattern of inheritance.

In this form of the condition the child may be born with fractures and the skull may be well ossified. In this condition there are white sclerae and there may be dentinogenesis imperfecta.

Growth is severely stunted and the child may be of short stature. Repeated fractures occur during childhood and there is progressive deformity of the limbs and spine. There may be kyphoscoliosis that is severe enough to predispose the child to chest disease.

Notes:

  • nearly all osteogenesis imperfecta (OI) cases are due to heterozygosity of dominant mutations in one or other of the two genes (COL1A1 and COL1A2) that encode for type I procollagen chains (1)
    • these type 1 procollagen chains form type I collagen, the major structural protein of the extracellular matrix of bone, skin and tendons
      • there have been more than 200 mutations identified so far
      • some mutations give rise to a qualitative type I collagen defect caused by a structural alteration of the collagen molecule. Other mutations maintain the synthesis of normal collagen, but in reduced quantity
        • mutations resulting in qualitative changes in type I collagen generally lead to the most severe forms of OI name
    • the broad clinical and biomolecular spectrum mean that any classification is unable to be complete or accurate - however it represents a practical tool for the clinician dealing with management of patients

Reference:

  1. Devogalaer JP. New uses of bisphosphonates: osteogenesis imperfecta. Curr Opin Pharmacol. 2002 Dec;2(6):748-53

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.